Animal models of psoriasis: A critical appraisal

Experimental Dermatology

Volumn 17, Issue 8, 2008, Pages 703-712

  Schön, Michael P ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Animal models; Psoriasis; Skin inflammation; Transgenic mouse

Indexed keywords

DNA; INTERLEUKIN 6; KERATINOCYTE GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ADAPTIVE IMMUNITY; ALGORITHM; ANGIOGENESIS; CELL FUNCTION; CLINICAL EFFECTIVENESS; DISEASE MODEL; DNA MODIFICATION; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; EXPERIMENTAL ANIMAL; GENE MUTATION; GENETIC ENGINEERING; GENETIC HETEROGENEITY; HISTOCOMPATIBILITY TEST; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INNATE IMMUNITY; KERATINOCYTE; LYMPHOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PENETRANCE; PHENOTYPE; PREDICTION; PROTEIN EXPRESSION; PROTEIN TARGETING; PSORIASIS; REVIEW; SKIN CELL; SKIN DISEASE; SKIN INFLAMMATION; T LYMPHOCYTE; TRANSGENIC MOUSE; XENOTRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; IMMUNITY, NATURAL; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MUTATION; PSORIASIS; SKIN; SKIN TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 47949117666     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00751.x     Document Type: Review

References (86)

1. Griffiths C E, Barker J N. Pathogenesis and clinical features of psoriasis. Lancet 2007: 370: 263-271.
2. Lowes M A, Bowcock A M, Krueger J G. Pathogenesis and therapy of psoriasis. Nature 2007: 445: 866-873.
3. Sabat R, Philipp S, Höflich C et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007: 16: 779-798.
4. Schön M P, Boehncke W H Psoriasis. N Engl J Med 2005: 352: 1899-1912.
5. Bos J D. Psoriasis, innate immunity, and gene pools. J Am Acad Dermatol 2007: 56: 468-471.
6. Bowcock A M, Krueger J G. Getting under the skin: The immunogenetics of psoriasis. Nat Rev Immunol 2005: 5: 699-711.
7. Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol 2007: 25: 563-567.
8. Gudjonsson J E, Johnston A, Dyson M, Valdimarsson H, Elder J T. Mouse models of psoriasis. J Invest Dermatol 2007: 127: 1292-1308.
9. Schön M P. Animal models of psoriasis - what can we learn from them? J Invest Dermatol 1999: 112: 405-410.
10. Dunstan R W, Rosser E R. Does a condition like human pityriasis rosea occur in pigs? Am J Dermatopathol 1986: 8: 86-89.
11. Jayo M J, Zanolli M D, Jayo J M. Psoriatic plaques in Macaca fascicularis. Vet Pathol 1988: 25: 282-285.
12. Lowe N J, Breeding J, Kean C, Cohn M L. Psoriasiform dermatitis in a rhesus monkey. J Invest Dermatol 1981: 76: 141-142.
13. Mason K V, Halliwell R E, McDougal B J. Characterization of lichenoid-psoriasiform dermatosis in springer spaniels. J Am Vet Med Assoc 1996: 189: 897-901.
14. Gates A H, Karasek M. Hereditary absence of sebaceous glands in the mouse. Science 1965: 148: 1471-1473.
15. HogenEsch H, Gijbels M J J, Zurcher C The chronic proliferative dermatitis (cpd) mutation, chromosome? In: Sundberg J P ed. Handbook of Mouse Mutations with Skin and Hair Abnormalities. Animal Models and Biomedical Tools. Boca Raton: CRC Press, 1994: 217-220.
16. Sundberg J P, France M, Boggess D et al. Development and progression of psoriasiform dermatitis and systemic lesions in the flaky skin (fsn) mouse mutant. Pathobiology 1997: 65: 271-286.
17. Atochina O, Harn D. Prevention of psoriasis-like lesions development in fsn/fsn mice by helminth glycans. Exp Dermatol 2006: 15: 461-468.
18. Beamer W G, Pelsue S C, Shultz L D, Sundberg J P, Barker J E. The flaky skin (fsn) mutation in mice: Map location and description of the anemia. Blood 1995: 86: 3220-3226.
19. Gijbels M J, Elliott G R, HogenEsch H, Zurcher C, van den Hoven A, Bruijnzeel P L. Therapeutic interventions in mice with chronic proliferative dermatitis (cpdm/cpdm). Exp Dermatol 2000: 9: 351-358.
20. Sundberg J P, Boggess D, Shultz L D, Beamer W G The flaky skin (fsn) mutation, chromosome? In: Sundberg J D ed. Handbook of Mouse Mutations with Skin and Hair Abnormalities. Boca Raton: CRC Press, 1994: 253-268.
21. Sundberg J P, Dunstan R W, Roop D R, Beamer W G. Full-thickness grafts from flaky skin mice to nude mice: Maintenance of the psoriasiform phenotype. J Invest Dermatol 1994: 102: 781-788.
22. Vassar R, Fuchs E. Transgenic mice provide new insights into the role of TGFa during epidermal development and differentiation. Genes Dev 1991: 5: 714-727.
23. Turksen K, Kupper T, Degenstein L, Williams I, Fuchs E. Interleukin 6: insights to its function by overexpression in transgenic mice. Proc Natl Acad Sci USA 1992: 89: 5068-5072.
24. Guo L, Yu Q C, Fuchs E. Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial differentiation in transgenic mice. EMBO J 1993: 12: 973-986.
25. Groves R W, Mizutani H, Kieffer J D, Kupper T S Inflammatory skin disease in transgenic mice that express high levels of interleukin 1a in basal epidermis. Proc Natl Acad Sci USA 1995: 92: 11874-11878.
26. Li A G, Wang D, Feng X H, Wang X J. Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J 2004: 23: 1770-1781.
27. Detmar M, Brown L F, Schön M P et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998: 111: 1-6.
28. Xia Y P, Li B, Hylton D, Detmar M, Yancopoulos G D, Rudge J S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory phenotype resembling human psoriasis. Blood 2003: 102: 161-168.
29. Carroll J M, Crompton T, Seery J P, Watt F M. Transgenic mice expressing IFN-γ in the epidermis have eczema, hair hypopigmentation, and hair loss. J Invest Dermatol 1997: 108: 412-422.
30. Blessing M, Schirmacher P, Kaiser S. Overexpression of bone morphogenic protein-6 (BMP-6) in the epidermis of transgenic mice: Inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions. J Cell Biol 1996: 135: 227-239.
31. Voskas D, Jones N, van Slyke P et al. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 2005: 166: 843-855.
32. Cook P W, Piepkorn M, Clegg C H et al. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J Clin Invest 1997: 100: 2286-2294.
33. Kopp T, Kieffer J D, Rot A, Strommer S, Stingl G, Kupper T S. Inflammatory skin disease in K14/p40 transgenic mice: Evidence for interleukin-12-like activities of p40. J Invest Dermatol 2001: 117: 618-626.
34. Kopp T, Lenz P, Bello-Fernandez C, Kastelein R A, Kupper T S, Stingl G. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: Evidence for enhanced cutaneous immunity. J Immunol 2003: 170: 5438-5444.
35. Blumberg H, Conklin D, Xu W F et al. Interleukin 20: Discovery, receptor identification, and role in epidermal function. Cell 2001: 104: 9-19.
36. D'Armiento J, DiColandrea T, Dalal S S et al. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol Cell Biol 1995: 15: 5732-5739.
37. Hobbs R M, Silva-Vargas V, Groves R, Watt F M. Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J Invest Dermatol 2004: 123: 503-515.
38. Carroll J M, Romero M R, Watt F M. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell 1995: 83: 957-968.
39. Bullard D C, Scharffetter-Kochanek K, McArthur M J et al. A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice. Proc Natl Acad Sci USA 1996: 93: 2116-2121.
40. Shepherd J, Little M C, Nicklin M J. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J Invest Dermatol 2004: 122: 665-669.
41. Hida S, Ogasawara K, Sato K et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000: 13: 643-655.
42. Schön M P, Schön M, Warren H B, Donohue J P, Parker C M. Cutaneous inflammatory disorder in integrin alphaE (CD103)-deficient mice. J Immunol 2000: 165: 6583-6589.
43. Pasparakis M, Courtois G, Hafner M et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK-2. Nature 2002: 417: 861-866.
44. Sano S, Chan K S, Carbajal S et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005: 11: 43-49.
45. Zenz R, Eferl R, Kenner L et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005: 437: 369-375.
46. Hammer R E, Maika S D, Richardson J A, Tang J P, Taurog J D. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human b2m: An animal model of HLA-B27-associated human disorders. Cell 1990: 63: 1099-1112.
47. Breban M, Fernandez-Sueiro J L, Richardson J A et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996: 156: 794-803.
48. Hong K, Chu A, Ludviksson B R, Berg E L, Ehrhardt R O. IL-12, independently of IFNgamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999: 162: 7480-7491.
49. Schön M P, Detmar M, Parker C M. Murine psoriasis-like disorder induced by naive CD4+ T-cells. Nat Med 1997: 3: 183-188.
50. Leon F, Contractor N, Fuss I et al. Antibodies to complement receptor 3 treat established inflammation in murine models of colitis and a novel model of psoriasiform dermatitis. J Immunol 2006: 177: 6974-6982.
51. Nickoloff B J. Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 2006: 12: 102-106.
52. Stratis A, Pasparakis M, Rupec R A et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 2006: 116: 2094-2104.
53. Nickoloff B J, Xin H, Nestle F O, Qin J Z. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007: 25: 568-573.
54. Nickoloff B J. Skin innate immune system in psoriasis: Friend or foe? J Clin Invest 1999: 104: 1161-1164.
55. Mössner R, Schön M P, Reich K Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol 2008: In press: doi:.
56. Wang H, Peters T, Kess D et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 2006: 116: 2105-2114.
57. Clark R A, Kupper T S Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest 2006: 116: 2084-2087.
58. Schön M, Denzer D, Kubitza R, Ruzicka T, Schön M P. Critical role of neutrophils for the generation of psoriasiform skin lesions in Flaky Skin mice. J Invest Dermatol 2000: 114: 976-983.
59. Kess D, Peters T, Zamek J et.al. CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J Immunol 2003: 171: 5697-5706.
60. Murphy M, Kerr P, Grant-Kels J M. The histopathologic spectrum of psoriasis. Clin Dermatol 2007: 25: 524-528.
61. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol 2007: 25: 510-518.
62. Igney F H, Asadullah K, Zollner T M. Humanised mouse models in drug discovery for skin inflammation. Expert Opin Drug Discov 2006: 1: 53-68.
63. Flanagan S P. 'Nude,' a new hairless gene with pleiotropic effects in the mouse. Genet Res 1966: 8: 295-309.
64. Bosma G C, Custer R P, Bosma M J. A severe combined immunodeficiency in the mouse. Nature 1983: 301: 527-530.
65. Bosma M J, Carroll A M. The SCID mouse mutant: Definition, characterization, and potential uses. Ann Rev Immunol 1991: 9: 323-350.
66. Mombaerts P, Iacomini J, Johnson R S, Herrup K, Tonegawa S, Papaioannou V E. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992: 68: 869-877.
67. Shinkai Y, Rathbun G, Lam K P et al. RAG-2 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J arrangement. Cell 1992: 68: 855-867.
68. Krueger G G, Manning D D, Malouf J, Ogden B. Long-term maintenance of psoriatic human skin on congenically athymic (nude) mice. J Invest Dermatol 1975: 64: 307-312.
69. Fraki J E, Briggaman R A, Lazarus G S. Uninvolved skin from psoriatic patients develop signs of involved skin after being grafted onto nude mice. Science 1982: 215: 685-686.
70. Boehncke W H. The SCID-hu xenogeneic transplantation model: Complex but telling. Arch Dermatol Res 1999: 291: 367-373.
71. Boehncke W H, Sterry W, Hainzl A, Scheffold W, Kaufmann R. Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto scid mice. Arch Dermatol Res 1994: 286: 325-330.
72. Nickoloff B J, Kunkel S L, Burdick M, Strieter R M. Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 1995: 146: 580-588.
73. Boehncke W -H, Dressel D, Zollner T M, Kaufmann R. Pulling the trigger on psoriasis (letter). Nature 1996: 379: 777.
74. Wrone-Smith T, Nickoloff B J Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996: 98: 1878-1887.
75. Conrad C, Boyman O, Tonel G et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 2007: 13: 836-842.
76. Boyman O, Hefti H P, Conrad C, Nickoloff B J, Suter M, Nestle F O. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumour necrosis factor alpha. J Exp Med 2004: 199: 731-736.
77. Boehncke W -H, Wortmann S, Kaufmann R, Mielke V, Sterry W. A subset of macrophages located along the basement membrane ('lining cells') is a characteristic histopathological feature of psoriasis. Am J Dermatopath 1995: 17: 139-144.
78. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980: 29: 1-13.
79. Roder J, Duwe A. The beige mutation in the mouse selectively impairs natural killer cell function. Nature 1979: 278: 451-453.
80. Christianson S W, Greiner D L, Hesselton R A et al. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J Immunol 1997: 158: 3578-3586.
81. Ishikawa F, Yasukawa M, Lyons B L et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain null mice. Blood 2005: 106: 1565-1573.
82. Shultz L D, Lyons B L, Burzenski L M et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005: 174: 6477-6489.
83. Kamel-Reid S, Dick J E. Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 1988: 242: 1706-1709.
84. Boehncke W H. The psoriasis SCID mouse model: A tool for drug discovery? Ernst Schering Res. Found Workshop 2005: 50: 213-234.
85. Boehncke W H, Schön M P. Animal models of psoriasis. Clin Dermatol 2007: 25: 596-605.
86. Nickoloff B J. Psoriatic animal model validation index. J Invest Dermatol 2006: 126: 59 (abstract).